The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.
Antoine Chaillon1, Adriane Wynn1, Tatyana Kushner2, Nancy Reau3, Natasha K Martin14
Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Population Health Sciences, University of Bristol, Bristol, United Kingdom.
To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.